NEW YORK (GenomeWeb News) – The American College of Obstetricians and Gynecologists has issued an opinion that non-invasive prenatal testing using cell-free fetal DNA can be offered to patients at increased risk of aneuploidy — a decision that is favorable to firms such as Sequenom, Ariosa Diagnostics, and Verinata Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.